Eli Lilly’s net income contracts to £920 million in the fiscal third quarter

Eli Lilly & Co. (NYSE: LLY) said on Tuesday that its earnings in the fiscal third quarter came in lower than expected. Eli Lilly is one of the prominent names that is committed to developing an effective treatment for COVID-19. It started late-stage human trials for its candidate vaccine in June. Shares of the company slid more than 6% in premarket trading on Tuesday. Including the price action, Eli Lilly & Co now has a per-share price of £102 that translates to more than 10% recovery since the year to date low of £91 per share in March due to